Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3831201 Target Snapshot

20S proteasome · PROTEIN COMPLEX GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
422Compounds
102Assays
1Approved Drugs
316.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

20S proteasome shows late clinical disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P49721. Start with glioblastoma multiforme, then reuse UniProt P49721 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with glioblastoma multiforme, then reuse UniProt P49721 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
glioblastoma multiforme

20S proteasome shows late clinical disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with glioblastoma multiforme because it currently carries late clinical support. Linked drugs include MARIZOMIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 20S proteasome as ChEMBL target CHEMBL3831201, mapped to UniProt P49721. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
20S proteasome
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3831201
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P49721
Proteasome subunit beta type-2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 20S proteasome is the right protein anchor across sources, using UniProt P49721 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why glioblastoma multiforme is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name20S proteasome
Target TypePROTEIN COMPLEX GROUP
OrganismHomo sapiens
UniProtP49721
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProteasome subunit beta type-2
UniProt AccessionP49721
Component TypeProtein
Sequence Length201 aa

Proteasome subunit beta type-2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 20S proteasome, mapped to UniProt P49721. ChEMBL maps the protein component as Proteasome subunit beta type-2. Sequence length is 201 aa.

Mapped IDP49721
Review name20S proteasome
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

20S proteasome shows late clinical disease relevance led by glioblastoma multiforme. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIZOMIB
Clinical signal Phase II
anaplastic ependymoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIZOMIB
Clinical signal Phase II
ependymoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIZOMIB
Clinical signal Phase II
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIZOMIB
Clinical signal Phase II
Paraganglioma
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIZOMIB
Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIZOMIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with glioblastoma multiforme because it currently carries late clinical support. Linked drugs include MARIZOMIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseglioblastoma multiforme
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
3
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50312.0
KI1.0
EC503.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL447239 9.22 IC50 0.6 Preclinical
CHEMBL5624541 9.22 Ki 0.6 Preclinical
CHEMBL4102324 9.04 IC50 0.92 Preclinical
CHEMBL384099 9.0 IC50 1.0 Preclinical
CHEMBL371405 8.89 IC50 1.3 Clinical
CHEMBL4460323 8.82 IC50 1.5 Preclinical
CHEMBL307387 8.7 IC50 2.0 Preclinical
CHEMBL5419917 8.66 IC50 2.2 Preclinical
CHEMBL4517600 8.62 IC50 2.4 Preclinical
CHEMBL5413513 8.62 IC50 2.4 Preclinical
Distribution

pChEMBL Value Distribution

10
5.0
28
5.5
18
6.0
25
6.5
42
7.0
39
7.5
44
8.0
9
8.5
4
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CARFILZOMIB
CHEMBL451887
Approved 2009
Properties Compare Identifier
Assay Landscape

Assay Landscape

102
Total Assays
190
Tested Compounds
3
Assay Types
Binding — 98 assays, 190 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 73 147 7.3
assay format 14 1 7.0
cell-based format 7 1 7.4
subcellular format 3 29 7.2
tissue-based format 1 12 6.1
Functional — 3 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
subcellular format 3 13 5.9
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine